Outcomes of acute coronary syndromes in coronavirus disease 2019

Victoria L. Cammann¹ · Konrad A. Szawan¹ · Fabrizio D'Ascenzo² · Sebastiano Gili³ · Sara Dreiding¹ · Michael Würdinger¹ · Robert Manka¹ · Barbara E. Stähli¹ · Erik W. Holy¹ · Patrick Siegrist¹ · Philipp Jakob¹ · Philippe Meyer⁴ · Mario Iannaccone⁵ · Emanuela Di Simone⁵ · Gioel Gabrio Secco⁶ · Matteo Saccocci⁷ · Luca Bettari⁸ · Alfonso Ielasi⁹ · Maurizio Tespili⁹ · Giorgio Quadri¹⁰ · Ferdinando Varbella¹⁰ · Sergio Raposeiras-Roubin¹¹ · Emad Abu-Assi¹¹ · Massimo Mancone¹² · Gennaro Sardella¹² · Fabio Infusino¹² · Francesco Fedele¹² · Giuseppe Patti¹³ · Marco Mennuni¹⁴ · Andrea Rognoni¹⁴ · Mario Bollati¹⁵ · Luca Olivotti¹⁶ · Stefano Cordone¹⁷ · Stefano Carugo¹⁸ · Lucia Barbieri¹⁸ · Luca Gaido¹⁹ · Massimo Giammaria¹⁹ · Alfonso Gambino²⁰ · Maurizio D'Amico²⁰ · Alessandro Galluzzo⁵ · Fabrizio Ugo⁵ · Daniela Trabattoni³ · Ovidio De Filippo² · Gaetano Maria De Ferrari² · Carmine Vecchione²¹ · Rodolfo Citro²¹ · Jelena R. Ghadri¹ · Christian Templin¹

Received: 24 July 2020 / Accepted: 3 September 2020 / Published online: 19 September 2020
© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Sirs:

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a fast spreading disease with high morbidity and mortality [1]. COVID-19 can contribute to severe myocardial injury,

ultimately culminating in acute coronary syndromes (ACS) [2]. Clinical features and outcomes of patients with SARS-CoV-2 associated ACS have not been elucidated, yet.

In a multicenter study, COVID-19 positive patients diagnosed with angiographically confirmed ACS between February 19 and April 9 2020 at 17 sites in Italy, Spain, and

Victoria L. Cammann, Konrad A. Szawan, Jelena R. Ghadri and Christian Templin contributed equally to this work.

✉ Christian Templin
Christian.Templin@usz.ch

- ¹ Andreas Grüntzig Heart Catheterization Laboratories and Acute Cardiac Care, University Heart Center, Department of Cardiology, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland
- ² Division of Cardiology, Department of Medical Sciences, AOU Città Della Salute E Della Scienza, University of Turin, Turin, Italy
- ³ Centro Cardiologico Monzino, IRCCS, Milan, Italy
- ⁴ Service de Cardiologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland
- ⁵ Department of Cardiology, San Giovanni Bosco Hospital, Turin, Italy
- ⁶ Interventional Cardiology and Cardiac Surgery Unit, Azienda Ospedaliera SS Antonio E Biagio E Cesare Arrigo, Alessandria, Italy
- ⁷ Cardiac Surgery Unit, Cardiovascular Department - Poliambulanza Foundation Hospital, Brescia, Italy
- ⁸ Interventional Cardiology Unit, Cardiovascular Department - Poliambulanza Foundation Hospital, Brescia, Italy
- ⁹ Clinical and Interventional Cardiology Unit, Sant'Ambrogio Cardio-Thoracic Center, Milan, Italy

- ¹⁰ Cardiology Unit, Rivoli Hospital, Turin, Italy
- ¹¹ Cardiology Department, University Hospital Alvaro Cunqueiro, Vigo, Spain
- ¹² Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy
- ¹³ University of Eastern Piedmont, Interventional Cardiology, Maggiore Della Carità Hospital of Novara, Novara, Italy
- ¹⁴ Interventional Cardiology, Maggiore Della Carità Hospital of Novara, Novara, Italy
- ¹⁵ Cardiology Division, Ospedale Maggiore, Lodi, Italy
- ¹⁶ Department of Cardiology, Ospedale Santa Corona, Pietra Ligure, Savona, Italy
- ¹⁷ Department of Cardiology, Ospedale San Paolo, Savona, Italy
- ¹⁸ Division of Cardiology, ASST Santi Paolo E Carlo, Milan, Italy
- ¹⁹ Division of Cardiology, Maria Vittoria Hospital, Turin, Italy
- ²⁰ Interventional Cardiology, S. Croce Hospital of Moncalieri, Turin, Italy
- ²¹ Heart Department, University Hospital "San Giovanni Di Dio E Ruggi D'Aragona", Salerno, Italy

Table 1 Characteristics of ACS Patients

	COVID-19 positive <i>N</i> = 45	COVID-19 negative <i>N</i> = 76	<i>P</i> value
Demographics			
Male sex—no./total no. (%)	37/45 (82.2)	59/76 (77.6)	0.55
Age (years)	69.7 ± 11.1 (<i>N</i> = 45)	65.8 ± 10.7 (<i>N</i> = 76)	0.06
BMI (kg/m ²)	26.5 ± 3.2 (<i>N</i> = 44)	27.7 ± 4.9 (<i>N</i> = 74)	0.11
ACS type			
STE-ACS	27/45 (60.0)	43/76 (56.6)	0.71
NSTE-ACS	18/45 (40.0)	33/76 (43.4)	0.71
Symptoms on admission—no./total no. (%)			
Chest pain	34/45 (75.6)	54/71 (76.1)	0.95
Dyspnea	23/45 (51.1)	14/71 (19.7)	<0.001
Cardiac biomarkers—median (IQR)			
Troponin maximum—factor increase in ULN ^a	97.36 (33.44–411.78) <i>N</i> = 43	139.46 (17.16–410.14) <i>N</i> = 76	0.79
Creatine kinase maximum—factor increase in ULN	6.55 (1.39–20.96) <i>N</i> = 27	4.16 (0.94–10.48) <i>N</i> = 76	0.14
BNP maximum—factor increase in ULN ^b	2.56 (0.92–22.26) <i>N</i> = 20	4.03 (1.62–11.05) <i>N</i> = 72	0.80
Inflammatory markers—median (IQR)			
CRP maximum (mg/l)	15.20 (7.95–60.68) <i>N</i> = 36	26.00 (6.80–62.00) <i>N</i> = 75	0.59
WBC maximum (10 ³ /μl)	11.94 (9.44–16.58) <i>N</i> = 44	11.16 (8.42–15.56) <i>N</i> = 75	0.15
Vital signs—mean ± SD			
Heart rate on admission (beats/min)	82.4 ± 16.0 (<i>N</i> = 37)	79.5 ± 15.7 (<i>N</i> = 76)	0.37
Systolic blood pressure on admission (mmHg)	131.6 ± 26.6 (<i>N</i> = 45)	134.0 ± 27.4 (<i>N</i> = 76)	0.64
Diastolic blood pressure on admission (mmHg)	78.1 ± 16.1 (<i>N</i> = 45)	77.9 ± 14.6 (<i>N</i> = 76)	0.94
LVEF (%)	42.5 ± 11.4 (<i>N</i> = 43)	44.7 ± 13.1 (<i>N</i> = 53)	0.40
ECG on admission			
Sinus rhythm—no./total no. (%)	41/45 (91.1)	70/74 (94.6)	0.48
QTc (ms)	430.2 ± 28.0 (<i>N</i> = 31)	435.9 ± 34.5 (<i>N</i> = 74)	0.42
Cardiovascular risk factors/comorbidities—no./total no. (%)			
Arterial hypertension	36/45 (80.0)	39/76 (51.3)	0.002
Diabetes mellitus	12/44 (27.3)	19/76 (25.0)	0.78
Hypercholesterolemia	19/45 (42.2)	42/76 (55.3)	0.17
Cancer	2/45 (4.4)	6/76 (7.9)	0.71*
Cerebrovascular disease	3/45 (6.7)	7/76 (9.2)	0.74*
COPD/asthma	2/45 (4.4)	7/76 (9.2)	0.48*
Coronary artery disease	13/45 (28.9)	22/76 (28.9)	1.0
Renal disease	5/45 (11.1)	10/76 (13.2)	0.74
Medication on admission—no./total no. (%)			
ACE inhibitor	15/45 (33.3)	15/71 (21.1)	0.14
AT antagonist	7/45 (15.6)	20/71 (28.2)	0.12
Beta-blocker	16/45 (35.6)	18/71 (25.4)	0.24
Calcium-channel antagonist	8/45 (17.8)	13/71 (18.3)	0.94
Statin	16/45 (35.6)	29/71 (40.8)	0.70*
Coumarin	1/45 (2.2)	4/71 (5.6)	0.64
Direct oral anticoagulant	1/45 (2.2)	1/71 (1.4)	1.0*
COVID-19 specific therapy—no./total no. (%)			
Hydroxychloroquine	24/45 (53.3)		
Remdesivir	1/45 (2.2)		
Lopinavir/Ritonavir	12/45 (26.7)		
Baricitinib	1/45 (2.2)		
Tocilizumab	3/45 (6.7)		

Table 1 (continued)

	COVID-19 positive N=45	COVID-19 negative N=76	P value
Acute cardiac care treatment—no./total no. (%)			
Catecholamine use	9/37 (24.3)	12/76 (15.8)	0.27
Invasive or non-invasive ventilation	17/45 (37.8)	12/76 (15.8)	0.006
Cardiopulmonary resuscitation	6/37 (16.2)	13/76 (17.1)	0.91
In-hospital death—no./total no. (%)	12/44 (27.3) ^o	6/76 (7.9)	0.004

ACE angiotensin converting enzyme, ACS acute coronary syndrome, AT angiotensin, BMI body mass index, BNP brain natriuretic peptide, COPD chronic obstructive pulmonary disease, COVID-19 coronavirus disease 2019, CRP c-reactive protein, ECG electrocardiogram, IQR inter-quartile range, LVEF left ventricular ejection fraction, NSTE non-ST-segment elevation, QTc QT time corrected for heart rate, SD standard deviation, STE ST-segment elevation, ULN upper limit of the normal, WBC white blood cell count

[†]Including upper limits of troponin T, high-sensitivity troponin T and troponin I

[§]Including upper limits of brain natriuretic peptide and the N-terminal of prohormone brain natriuretic peptide

^oOne patient was still hospitalized at time of performing statistical analysis

*Fisher's exact test

Switzerland were compared to COVID-19 negative ACS patients from the University Hospital Zurich. In addition, patients with ST-segment elevation (STE)-ACS COVID 19 positive vs. COVID-19 negative were compared as well as patients with non-ST-segment elevation (NSTEMI)-ACS COVID-19 positive vs. COVID-19 negative.

Out of 4702 patients with COVID-19, 45 (0.96%) had ACS, of which 27 (60.0%) had STE-ACS and 18 (40.0%) NSTEMI-ACS. Single vessel disease was present in 25 patients (55.6%) of COVID-19 positive ACS and multi vessel disease in 20 patients (44.4%), respectively. All patients received percutaneous coronary intervention.

COVID-19 positive ACS patients were more likely to present with dyspnea (51.1% vs. 19.7%; $P < 0.001$) and arterial hypertension (80.0% vs. 51.3%; $P = 0.002$), while other patients' characteristics were largely comparable to COVID-19 negative ACS patients (Table 1). Of note, in-hospital mortality was more than 3 times higher in COVID-19 positive ACS patients than in COVID-19 negative ACS patients (27.3% vs. 7.9%; $P = 0.004$, Table 1). Furthermore, when stratifying patients according to the presence or absence of ST-segment elevation, COVID-19 positive patients with STE-ACS had higher mortality rates compared to COVID-19 negative STE-ACS patients (33.3% vs. 9.3%; $P = 0.024$) and also COVID-19 positive patients with NSTEMI-ACS showed numerically higher mortality rates compared to COVID-19 negative NSTEMI-ACS patients (17.6% vs. 6.1%; $P = 0.32$). Importantly, 9 out of 12 (75%) deceased COVID-19 positive ACS patients had involvement of multiple organ systems in addition to cardiac manifestations, thus indicating a systemic vascular damage. In comparison to recovered COVID-19 positive ACS patients, deceased COVID-19 positive ACS patients had markedly elevated troponin values (factor increase in upper limit of the normal (ULN): 65.00 vs. 323.00; $P = 0.014$) and brain natriuretic peptide

values (factor increase in ULN: 2.00 vs. 113.23; $P = 0.023$) accompanied by severely depressed left ventricular ejection fraction ($45.3 \pm 10.3\%$ vs. $34.3 \pm 9.5\%$; $P = 0.003$) suggesting incremental SARS-CoV-2 related myocardial injury further aggravating ACS related heart failure.

The relatively low frequency of ACS in COVID-19 may in part explained by the fact that not all COVID-19 positive patients who exhibit ST-segment elevation undergo coronary angiography [3]. The concomitant occurrence of COVID-19 and ACS might be responsible for the increased mortality. Pathophysiological mechanisms underlying COVID-19 related ACS events are unknown but might include acute plaque rupture or erosion facilitated by systemic inflammation, microvascular thrombosis due to hypercoagulability, and/or endothelial dysfunction [4]. The latter is known to play a key role in arterial hypertension and thrombosis and has recently been associated with COVID-19 [5]. In this respect, endotheliitis in COVID-19 might affect various vascular beds thereby increasing the susceptibility for thromboembolic and septic complications or multi-organ-failure [5]. Thus, myocardial ischemia due to ACS might be even aggravated by COVID-19 induced generalized microvascular dysfunction and systemic vascular damage leading to severe heart failure with unfavorable outcomes. Therefore, in addition to a guideline-directed ACS management, therapies to improve endothelial dysfunction might be considered in patients with COVID-19.

Funding None.

Compliance with ethical standards

Conflict of interest The authors report no conflicts of interest.

References

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan. *China Lancet* 395(10223):497–506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5)
2. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang H, Yang B, Huang C (2020) Association of Cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. *JAMA Cardiol.* <https://doi.org/10.1001/jamacardio.2020.0950>
3. Bangalore S, Sharma A, Slotwiner A, Yatskar L, Harari R, Shah B, Ibrahim H, Friedman GH, Thompson C, Alviari CL, Chadow HL, Fishman GI, Reynolds HR, Keller N, Hochman JS (2020) ST-segment elevation in patients with Covid-19—a case series. *N Engl J Med.* <https://doi.org/10.1056/NEJMc2009020>
4. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O (2020) Potential effects of coronaviruses on the cardiovascular system: a review. *JAMA Cardiol.* <https://doi.org/10.1001/jamacardio.2020.1286>
5. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H (2020) Endothelial cell infection and endotheliitis in COVID-19. *Lancet.* [https://doi.org/10.1016/S0140-6736\(20\)30937-5](https://doi.org/10.1016/S0140-6736(20)30937-5)